Surgery followed by tailored treatment for advanced cervical cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This international, multicenter, randomized open-label phase III study aims to evaluate the effectiveness of para-aortic lymphadenectomy followed by tailored chemoradiation in patients with stage IIIC1 cervical cancer. Participants will be randomly assigned to either a control arm receiving standard chemoradiotherapy or an experimental arm undergoing the surgical procedure before treatment. The study plans to enroll 510 patients, with a significant portion from France, and will follow participants for five years to assess disease-free survival rates. Additionally, a cost-utility analysis will be conducted for patients in France to evaluate the economic impact of the intervention.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Age ≥ 18 years at time of study entry
2. Newly diagnosed histologically proven cervical squamous carcinoma, adenocarcinoma, or adenosquamous tumor
3. FIGO stage IIIC1 (FIGO 2018) cervical cancer with FDG-PET/CT showing FDG-positive pelvic nodes and FDG-negative PALN including equivocal lymph nodes in the common iliac and para-aortic regions. The highest positive lymph node must be located inferior to the common iliac bifurcation in both sides (anatomical level 1).
4. Patients with TNM T stage I-IIIB.
5. FIGO stage IIIC1 cervical cancer by positive pelvic sentinel lymph node from surgical staging (either intraoperative assessment (frozen section) or from final histology - patients are not eligible after radical hysterectomy, and FDG-negative common iliac of para-aortic lymph node on PET/CT (performed before or after SLN procedure)
6. Patient eligible for pelvic radiotherapy and cisplatin-based chemotherapy with a curative intent as confirmed by a multidisciplinary board
7. ECOG performance status \< 2 i.e. 0 or 1
8. Life expectancy more than 12 months
9. Pretherapeutic imaging FDG-PET/CT images should be available for central review
10. Prior validation of the surgeon's participation in the study by the Quality Assurance Comity
11. Women should be post-menopaused or willing to accept the use of an effective contraceptive regimen during the treatment period. All non-menopaused women should have a negative pregnancy test within 72 hours prior to study entry.
12. Patient is willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examinations including follow up
13. Not applicable since protocol revision V4. Patient participating to other clinical trials including immunotherapy strategies or adjuvant chemotherapy is also eligible for the study. Adjuvant treatment must be decided prior to randomization
14. Signed informed consent
15. Patient affiliated to a Social Health Insurance in France (French patients only).

Exclusion Criteria:

1. Unequivocal positive common iliac or para-aortic lymph nodes at pretherapeutic imaging FDG-PET/CT
2. Negative or equivocal pelvic lymph nodes at pretherapeutic imaging FDG-PET/CT
3. Metastatic disease confirmed by FDG-PET/CT
4. Other histologies than adenocarcinoma, squamous cell carcinoma and adenosquamous carcinoma
5. Contraindication for cisplatin-based chemotherapy
6. Women who received any prior treatment for cervical cancer
7. Prior surgery for the cervical cancer, except for cone procedure and pelvic lymph node staging
8. Previous pelvic radiotherapy
9. History of another primary malignancy except for: Malignancy treated with curative intent and with no known active disease after 5 years, adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease, adequately treated carcinoma in situ (any location) without evidence of disease.
10. Any psychological, familial, geographic or social situation, according to the judgment of investigator, potentially preventing the provision of informed consent or compliance to study procedure
11. Patient who has forfeited his/her freedom by administrative or legal award or who is under legal protection (curatorship and guardianship, protection of justice).

Where it's running

• UH Ostrava - FNO
  Ostrava, Czechia Recruiting
• UH Plzeň
  Pilsen, Czechia Recruiting
• General UH in Prague - VFN
  Prague, Czechia Recruiting
• Institut de Cancérologie de l'Ouest
  Angers, France Recruiting
• Institut Bergonié
  Bordeaux, France Recruiting
• CHU Brest
  Brest, France Recruiting

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• T Cell Receptor Immunotherapy for Metastatic Non-Small Cell Lung Cancer

  This study is testing a new treatment for advanced lung cancer that uses special immune cells from patients' own tumors to see if it can help shrink their cancer.

  Recruiting Phase 2 National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT02133196

• A Community Approach to Boost Cervical Cancer Screening for Hispanic and East African Immigrant Women

  The study tests a community-based program that offers self-collection HPV tests and information to Hispanic and East African immigrant women to see if screening rates improve.

  Recruiting Mayo Clinic · Rochester, Minnesota · NCT07890402

• Flyte device to help urinary incontinence after pelvic radiation for endometrial or cervical cancer

  This study tests whether a home-use Flyte device, used during guided pelvic floor exercises, can improve urinary incontinence in women who had pelvic radiation for endometrial or cervical cancer.

  Recruiting Mayo Clinic · Rochester, Minnesota · NCT07662824

• Neoadjuvant nivolumab for cervical cancer using tumor-draining lymph nodes

  This study tests different doses of nivolumab injected near the tumor to see if the treatment is safe and feasible before standard surgery in newly diagnosed cervical cancer.

  Recruiting Phase 1 University Medical Center Groningen · Groningen · NCT07653503

• Methionine-Reduced Diet in Solid Tumors (early-phase)

  A small pilot study will test whether a methionine-reduced diet can change blood levels in adults with various solid tumors who are receiving standard cancer therapy.

  Recruiting Early Phase 1 University of California, Irvine · Orange, California · NCT07628634

• TriAdeno and N-803 vaccine in early prostate cancer on active surveillance

  A vaccine combo called TriAdeno plus the N-803 drug is being tested to see if it can help slow or stop growth in men with early-stage, low- to intermediate-risk prostate cancer who are being watched rather than treated right away.

  Recruiting Phase 2 National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT07574541

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.